The deal includes two recently approved GSK products for metastatic melanoma, Tafinlar and Mekinist, which will help Novartis break into this key cancer type, where BMS, Merck and Roche are all ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Novartis's product lineup is anchored by several key growth drivers, including Cosentyx, Pluvicto, Kisqali, and Scemblix. These products are expected to play a crucial role in achieving the ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Novartis said that the latest round of job losses is a result of a change in focus for its cardiovascular teams as they lower the emphasis on Entresto and devote more resources to its twice-yearly ...

Traditionally, pharmaceutical products have always been exempt from ... 12 years as chairman at the company's AGM on Friday, said Novartis assumed the financial impact of the tariffs would be ...

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion and recommended granting a marketing a ...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines ...